Phase II trial of HIV vaccines, RG 83894 and IR 103, in antiretroviral-naive patients with HIV infections
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs IR 103 (Primary) ; GP120-depleted HIV-1 vaccine
- Indications HIV infections
- Focus Therapeutic Use
- Sponsors Immune Response Corporation; Orchestra Therapeutics
- 18 Jul 2007 Status changed from in progress to discontinued.
- 19 Feb 2007 New trial record.